See the deficiency information page for an explanation of some of the columns in this list, references and other useful information. Deficiencies with 'Exel' in the symbol were donated under legal restrictions and require a license for commercial use.
Kai Zinn and colleagues have defined a subset of BDSC deficiency stocks that produce homozygous progeny with recognizable nervous systems and intact body walls. These deficiencies encompass >80% of the genome and they can be screened for deletion of genes encoding the ligands of orphan receptors or genes affecting protein localization. The paper describing this kit suggested an order in which the deficiencies should be screened.
- Deficiencies that can be balanced over a GFP-marked balancer and produce intact homozygous embryos.
- Similar deficiencies that may be redundant.
- Deficiencies that cannot be balanced with a GFP-marked balancer.
- Deficiencies producing homozygous embryos with very severe phenotypes.
In addition, Kai Zinn and colleagues defined a subset of these deficiencies that produce homozygous embryos with relatively normal development to late stage 16 (get stock numbers for this kit). This kit, which covers ~50% of the genome, can be used to screen for genes involved in embryonic organ development including axon pathfinding.
Primary reference: Wright et al. (2010) “Systematic Screening of Drosophila Deficiency Mutations for Embryonic Phenotypes and Orphan Receptor Ligands”, PLoS ONE 5(8):e12288.
Please cite those who generated and analyzed these materials when publishing your own work with these and other Stock Center stocks.
If you would like to order all of these stocks, then click here.